MHLW Approves Pfizer's Zithromax Slow Release Drug
This article was originally published in PharmAsia News
The second division on new drugs of the Pharmaceutical Affairs and Food Sanitation Council at Japan's Ministry of Health, Labor and Welfare approved Pfizer's slow-release Zithromax (azithromycin) for adult use. It is indicated to treat bacterial infection such as gonococcal infection. The re-examination period is four years. The slow release version of azithromycin allows one dose use to last for three days. (Click here for more - Japanese language
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.